A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

(2018) Julien Taieb et al.   CANCER TREATMENT REVIEWS

Human gastric cancer modelling using organoids

(2018) Therese Seidlitz et al.   GUT

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

(2018) Jianfeng Shen et al.   NATURE MEDICINE

A proteomic landscape of diffuse-type gastric cancer

(2018) Sai Ge et al.   Nature Communications

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

(2018) Hervé Tiriac et al.   Cancer Discovery

Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis

(2018) Kosaku Nanki et al.   CELL

PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene

(2018) Karol Polom et al.   Advances in Clinical and Experimental Medicine

A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening

(2018) Helen H.N. Yan et al.   Cell Stem Cell

Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers

(2017) Soo Young Cho et al.   GASTROENTEROLOGY

Patient-derived xenografts undergo mouse-specific tumor evolution

(2017) Uri Ben-David et al.   NATURE GENETICS

Cancer stem cells revisited

(2017) Eduard Batlle et al.   NATURE MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

The Role of Integrin α6 (CD49f) in Stem Cells: More than a Conserved Biomarker

(2017) Paul H. Krebsbach et al.   STEM CELLS AND DEVELOPMENT

Targeted therapies for gastric cancer: failures and hopes from clinical trials

(2017) Maria Apicella et al.   Oncotarget

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis

(2017) Lihu Gu et al.   PLoS One

Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability

(2016) Changqing Ma et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma

(2016) Phu Hung Nguyen et al.   CLINICAL CANCER RESEARCH

Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation

(2016) Laura Broutier et al.   Nature Protocols

Clinical impact of tumour biology in the management of gastroesophageal cancer

(2016) Florian Lordick et al.   Nature Reviews Clinical Oncology

β-Catenin-Independent Roles of Wnt/LRP6 Signaling

(2016) Sergio P. Acebron et al.   TRENDS IN CELL BIOLOGY

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

(2015) Ji Hyun Park et al.   BMC CANCER

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

In Vitro Expansion of Human Gastric Epithelial Stem Cells and Their Responses to Bacterial Infection

(2015) Sina Bartfeld et al.   GASTROENTEROLOGY

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

(2015) Razvan Cristescu et al.   NATURE MEDICINE

Histological mixed-type as an independent prognostic factor in stage I gastric carcinoma

(2015) Shuhei Komatsu   WORLD JOURNAL OF GASTROENTEROLOGY

Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing

(2015) Hiroshi Ikeda et al.   OncoTargets and Therapy

CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells

(2014) W. M. Lau et al.   CANCER RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic implication of TSC1 and mTOR expression in gastric carcinoma

(2014) Sun-ju Byeon et al.   JOURNAL OF SURGICAL ONCOLOGY

A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients

(2014) Seon-Kyu Kim et al.   Molecular Oncology

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer

(2014) Ying-Chun Shen et al.   ONCOLOGY

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

(2014) Swee Seong Wong et al.   Nature Communications

Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion

(2013) Jing Zhou et al.   CELL RESEARCH

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

CD49fhigh Cells Retain Sphere-Forming and Tumor-Initiating Activities in Human Gastric Tumors

(2013) Hiroshi Fukamachi et al.   PLoS One

Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach

(2012) Tomio Arai et al.   Gastric Cancer

Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-β

(2012) Yoko Katsuno et al.   JOURNAL OF PATHOLOGY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer

(2011) Shu Shimada et al.   GUT

mTOR as a therapeutic target in patients with gastric cancer

(2011) Salah-Eddin Al-Batran et al.   INTERNATIONAL JOURNAL OF CANCER

CD133 and CD44 Cell surface markers do not identify cancer stem cells in primary human gastric tumors

(2011) Alba Rocco et al.   JOURNAL OF CELLULAR PHYSIOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

(2011) J.-P. Gillet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitors of mTOR

(2010) H.-J. Klumpen et al.   ONCOLOGIST

Relation between outcomes and localisation of p-mTOR expression in gastric cancer

(2009) T Murayama et al.   BRITISH JOURNAL OF CANCER

Recent results of therapy for scirrhous gastric cancer

(2009) Masahide Ikeguchi et al.   SURGERY TODAY

Methylation of the Calcium Channel-Related Gene, CACNA2D3, Is Frequent and a Poor Prognostic Factor in Gastric Cancer

(2008) Aira Wanajo et al.   GASTROENTEROLOGY

Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas

(2008) Hua-chuan Zheng et al.   VIRCHOWS ARCHIV